Detalles de la búsqueda
1.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet Oncol
; 24(3): 286-296, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37052965
2.
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.
Gynecol Oncol
; 175: 182-189, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37355448
3.
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Lancet Oncol
; 22(2): 267-276, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33539744
4.
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Lancet Oncol
; 21(4): 497-507, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32164906
5.
Peritoneal carcinomatosis from ovarian paraganglioma: Report of a rare case and systematic review of the literature.
J Obstet Gynaecol Res
; 44(9): 1682-1692, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29978527
6.
Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19).
Gynecol Oncol
; 143(3): 532-538, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27717490
7.
Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study.
Cancer
; 120(3): 335-43, 2014 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24127346
8.
Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study.
Eur J Cancer
; 203: 114039, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38598922
9.
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.
J Clin Oncol
; 42(13): 1488-1498, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38315944
10.
Histopathological and Immunohistochemical Prognostic Factors in High-Grade Non-Endometrioid Carcinomas of the Endometrium (HG-NECs): Is It Possible to Identify Subgroups at Increased Risk?
Diagnostics (Basel)
; 13(13)2023 Jun 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37443564
11.
The Advantages of Next-Generation Sequencing Molecular Classification in Endometrial Cancer Diagnosis.
J Clin Med
; 12(23)2023 Nov 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38068290
12.
The prognostic value of FIGO staging defined by combining MRI and [18F]FDG PET/CT in patients with locally advanced cervical cancer.
Curr Probl Cancer
; 47(6): 101007, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37684197
13.
The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers.
Front Immunol
; 14: 1221605, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37680633
14.
Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society.
Tumori
; 109(5): 490-495, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36609207
15.
Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.
Front Oncol
; 13: 1247291, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37781174
16.
Reliability of patient-reported toxicities during adjuvant chemotherapy.
Eur J Cancer
; 182: 115-121, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36758476
17.
Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.
Front Oncol
; 13: 1357793, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38318323
18.
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study.
Cancers (Basel)
; 15(4)2023 Feb 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36831376
19.
A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites.
Gynecol Oncol
; 125(1): 42-7, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22112608
20.
Neoadjuvant Chemotherapy Followed by Radical Surgery versus Concurrent Chemo-Radiotherapy in the Treatment of Locally Advanced Cervical Cancer: A Multicenter Retrospective Analysis.
J Invest Surg
; 35(2): 308-314, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33289585